SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-043036
Filing Date
2024-05-14
Accepted
2024-05-14 17:15:31
Documents
14
Period of Report
2024-05-13
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0205945-8k_pasithea.htm   iXBRL 8-K 30364
  Complete submission text file 0001213900-24-043036.txt   249745

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ktta-20240513.xsd EX-101.SCH 3810
3 XBRL DEFINITION FILE ktta-20240513_def.xml EX-101.DEF 26681
4 XBRL LABEL FILE ktta-20240513_lab.xml EX-101.LAB 36819
5 XBRL PRESENTATION FILE ktta-20240513_pre.xml EX-101.PRE 25305
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0205945-8k_pasithea_htm.xml XML 5947
Mailing Address 2110 NARCISSUS CT VENICE CA 90291
Business Address 2110 NARCISSUS CT VENICE CA 90291 8184226172
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

IRS No.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40804 | Film No.: 24945704
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)